Home > Journals > Minerva Cardiology and Angiology > Past Issues > Articles online first > Minerva Cardiology and Angiology 2022 Apr 14

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

Original Article   

Minerva Cardiology and Angiology 2022 Apr 14

DOI: 10.23736/S2724-5683.22.06008-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Proprotein convertase subtilisin kexin type 9 and main arteries atherosclerosis in patients with arterial hypertension

Yulia VUKOLOVA 1 , Irina GUBAREVA 1, Giuseppe GALATI 2, Olga GERMANOVA 3

1 Department of Internal Medicine, Samara State Medical University, Samara, Russia; 2 Unit of Heart Failure, Division of Cardiology, Department of Cardiothoracic and Vascular, San Raffaele Scientific Institute, Milan, Italy; 3 International Center for Education and Research in Cardiovascular Pathology and Cardiovisualization, Samara State Medical University, Samara, Russia


PDF


BACKGROUND: Aim of our investigation is to study the relationship between the level of proprotein convertase subtilisin kexin type 9 (PCSK9) and atherosclerotic process of coronary and brachiocephalic arteries in patients with arterial hypertension (AH).
METHODS: Our investigation was performed in regional railway hospital. In our investigation we included 161 male train drivers who had AH with achieved target grades 1-2. All patients were performed laboratory tests including cholesterol, LDLC, triglycerides, glucose, hemostasiograms, PCSK9. Patients were divided into groups up to the PCSK9 level: in group 1 (n = 41) we included patients with PCSK9 level 108-250 ng/ml; group 2 (n = 37) 251 - 400 ng/ml; group 3 (n = 45) 420 - 560 ng/ml and group 4 (n = 38) 580 - 860 ng/ml. All patients were performed coronary angiography, ultrasound Doppler of brachiocephalic arteries, electrocardiography, transthoracic echocardiography.
RESULTS: The groups of the patients were identical in age, body mass index, triglycerides, LDL-C, glucose, cholesterol levels. Also, there was no significant difference in the dependence of PCSK9 level on smoking status (χ2=3,1; p=0,3) and the presence of family history of AH (χ2=0,9; p=0,8). It was found that in the 1st group, patients with normal body mass index had normal carotid intima-media thickness ≤1 mm in most of the cases (34,1%). The severity of brachiocephalic and coronary arteries atherosclerosis was more advanced in the 4th group. The atherosclerotic plaques determine the cardiovascular risk in patients with AH.
CONCLUSIONS: The level of PCSK9 in male patients is an additional cardiovascular risk factor independent from the traditional risk factors. The PCSK9 level is correlated with atherosclerotic severity process of brachiocephalic arteries (p=0,08; r=0,2). The concentration of PCSK9 in the blood serum more than 580 ng/ml in patients with AH determines more severe coronary arteries atherosclerosis. If more the level of PCSK9 than more cardiovascular risk (p=0,002).


KEY WORDS: Arterial hypertension; Atherosclerosis; PCSK9; Cardiovascular risk

top of page